A Rapid Q-PCR Titration Protocol for Adenovirus and Helper-dependent Adenovirus Vectors That Produces Biologically Relevant Results

Overview

Journal J Virol Methods

Specialty Microbiology

Date 2013 Apr 30

PMID 23624118

Citations 14

Authors

Sean D Gallaher

Arnold J Berk

Affiliations

Soon will be listed here.

Abstract

Adenoviruses are employed in the study of cellular processes and as expression vectors used in gene therapy. The success and reproducibility of these studies is dependent in part on having accurate and meaningful titers of replication competent and helper-dependent adenovirus stocks, which is problematic due to the use of varied and divergent titration protocols. Physical titration methods, which quantify the total number of viral particles, are used by many, but are poor at estimating activity. Biological titration methods, such as plaque assays, are more biologically relevant, but are time consuming and not applicable to helper-dependent gene therapy vectors. To address this, a protocol was developed called "infectious genome titration" in which viral DNA is isolated from the nuclei of cells ~3 h post-infection, and then quantified by Q-PCR. This approach ensures that only biologically active virions are counted as part of the titer determination. This approach is rapid, robust, sensitive, reproducible, and applicable to all forms of adenovirus. Unlike other Q-PCR-based methods, titers determined by this protocol are well correlated with biological activity.

Citing Articles

Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.

Bagdonaite I, Abdurahman S, Mirandola M, Pasqual D, Frank M, Narimatsu Y J Virol. 2024; 98(6):e0052424.

PMID: 38757972 PMC: 11237518. DOI: 10.1128/jvi.00524-24.

An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1.

Deng H, Ge H, Dubey C, Losmanova T, Medova M, Konstantinidou G Cancer Immunol Immunother. 2023; 72(12):4457-4470.

PMID: 37796299 PMC: 10700219. DOI: 10.1007/s00262-023-03542-z.

Rapid and stain-free quantification of viral plaque via lens-free holography and deep learning.

Liu T, Li Y, Koydemir H, Zhang Y, Yang E, Eryilmaz M Nat Biomed Eng. 2023; 7(8):1040-1052.

PMID: 37349390 PMC: 10427422. DOI: 10.1038/s41551-023-01057-7.

NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines.

Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K Curr Issues Mol Biol. 2023; 45(2):1073-1085.

PMID: 36826016 PMC: 9955465. DOI: 10.3390/cimb45020071.

NEAT1 Confers Radioresistance to Hepatocellular Carcinoma Cells by Inducing PINK1/Parkin-Mediated Mitophagy.

Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K, Shiota G Int J Mol Sci. 2022; 23(22).

PMID: 36430876 PMC: 9692527. DOI: 10.3390/ijms232214397.

References

Rots M, Curiel D, Gerritsen W, Haisma H . Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J Control Release. 2003; 87(1-3):159-65. DOI: 10.1016/s0168-3659(02)00360-7. View

Dorigo O, Gil J, Gallaher S, Tan B, Castro M, Lowenstein P . Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol. 2004; 78(12):6556-66. PMC: 416543. DOI: 10.1128/JVI.78.12.6556-6566.2004. View

Philipson L . Adenovirus assay by the fluorescent cell-counting procedure. Virology. 1961; 15:263-8. DOI: 10.1016/0042-6822(61)90357-9. View

Harui A, Suzuki S, Kochanek S, Mitani K . Frequency and stability of chromosomal integration of adenovirus vectors. J Virol. 1999; 73(7):6141-6. PMC: 112682. DOI: 10.1128/JVI.73.7.6141-6146.1999. View

Dai Y, Schwarz E, Gu D, Zhang W, Sarvetnick N, Verma I . Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995; 92(5):1401-5. PMC: 42527. DOI: 10.1073/pnas.92.5.1401. View

Kreppel F, Biermann V, Kochanek S, Schiedner G . A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther. 2002; 13(10):1151-6. DOI: 10.1089/104303402320138934. View

Gil J, Gallaher S, Berk A . Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice. Gene Ther. 2010; 17(10):1288-93. PMC: 3041831. DOI: 10.1038/gt.2010.75. View

Wang L, Wang C, Tan C, Hsu D, Hennessey J . A robust approach for the quantitation of viral concentration in an adenoviral vector-based human immunodeficiency virus vaccine by real-time quantitative polymerase chain reaction. Hum Gene Ther. 2006; 17(7):728-40. DOI: 10.1089/hum.2006.17.728. View

Ghosh S, Gopinath P, Ramesh A . Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol. 2006; 133(1):9-29. DOI: 10.1385/abab:133:1:9. View

10.

Rich D, Couture L, Cardoza L, Guiggio V, Armentano D, Espino P . Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther. 1993; 4(4):461-76. DOI: 10.1089/hum.1993.4.4-461. View

11.

Brunetti-Pierri N, Ng P . Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther. 2008; 15(8):553-60. PMC: 3668677. DOI: 10.1038/gt.2008.14. View

12.

Prevec L, Christie B, Laurie K, Bailey M, Graham F, Rosenthal K . Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acquir Immune Defic Syndr (1988). 1991; 4(6):568-76. View

13.

Li F, Feng L, Liu Y, Zhen X, Chen L . An integrated cell culture and quantitative polymerase chain reaction technique for determining titers of functional and infectious adenoviruses. Anal Biochem. 2009; 391(2):157-9. DOI: 10.1016/j.ab.2009.05.017. View

14.

Berget S, Moore C, Sharp P . Spliced segments at the 5' terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci U S A. 1977; 74(8):3171-5. PMC: 431482. DOI: 10.1073/pnas.74.8.3171. View

15.

Grabow W, Puttergill D, Bosch A . Propagation of adenovirus types 40 and 41 in the PLC/PRF/5 primary liver carcinoma cell line. J Virol Methods. 1992; 37(2):201-7. DOI: 10.1016/0166-0934(92)90047-h. View

16.

Mittereder N, March K, Trapnell B . Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996; 70(11):7498-509. PMC: 190817. DOI: 10.1128/JVI.70.11.7498-7509.1996. View

17.

Rosenfeld M, Yoshimura K, Trapnell B, Yoneyama K, Rosenthal E, Dalemans W . In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 1992; 68(1):143-55. DOI: 10.1016/0092-8674(92)90213-v. View

18.

Segura M, Monfar M, Puig M, Mennechet F, Ibanes S, Chillon M . A real-time PCR assay for quantification of canine adenoviral vectors. J Virol Methods. 2009; 163(1):129-36. DOI: 10.1016/j.jviromet.2009.09.010. View

19.

Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D . Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 1999; 6(7):1305-12. DOI: 10.1038/sj.gt.3300951. View

20.

Levine A . The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology. 2008; 384(2):285-93. DOI: 10.1016/j.virol.2008.09.034. View